Biosimilars face a potential void as biologics lose exclusivity, prompting urgent calls for policy reform and enhanced ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more ...

Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate ...

Number 5: Long-term data from the SAME study confirm that switching to infliximab biosimilars is safe and effective for ...

The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

Gary Fanjiang, MD, MBA, MS, is the vice president of global development at Amgen, where he leads research and development activities for the Biosimilars Business Unit. He oversees the nonclinical, ...

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for diabetes treatment.